Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cetrorelix
Drug ID BADD_D00419
Description Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.
Indications and Usage For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation
Marketing Status approved; investigational
ATC Code H01CC02
DrugBank ID DB00050
KEGG ID D07665
MeSH ID C062876
PubChem ID 25074887
TTD Drug ID D09OLZ
NDC Product Code 41524-0013; 78848-005
UNII OON1HFZ4BA
Synonyms cetrorelix | N-acetyl-1-(3-(2-naphthyl)alanine)-2-(4-chlorophenylalanine)-3-(3-(3-pyridyl)alanine)-6-citrulline-10-alanine-LHRH | LHRH, N-Ac-1-Nal(2)-2-Phe(pCl)-3-Pal(3)-6-Cit-10-Ala- | LHRH, N-acetyl-1-(3-(2-naphthyl)alanyl)-2-(4-chlorophenylalanyl)-3-(3-(3-pyridyl)alanyl)-6-citrulline-10-alanine- | SB 75 | SB-75 | Cetrotide | cetrorelix acetate | cetrorelix pamoate
Chemical Information
Molecular Formula C70H92ClN17O14
CAS Registry Number 120287-85-6
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O )C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(= O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anencephaly03.10.03.001; 17.19.03.001--Not Available
Assisted fertilisation25.10.04.001--Not Available
Congenital anomaly03.02.01.001--Not Available
Cough22.02.03.001--
Dermatitis23.03.04.002--Not Available
Developmental delay19.07.05.003; 08.01.03.037--Not Available
Developmental glaucoma06.03.02.001; 03.01.05.001--Not Available
Diaphragmatic hernia22.09.02.001; 07.16.01.002--Not Available
Erythema23.03.06.001--Not Available
Glaucoma06.03.01.002--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Imperforate hymen03.03.04.001; 21.08.01.004--Not Available
Klinefelter's syndrome03.20.05.001; 05.05.02.005--Not Available
Local reaction08.01.03.012--Not Available
Melanocytic naevus23.10.01.007; 16.26.01.007--Not Available
Menopausal symptoms21.02.02.002--Not Available
Nausea07.01.07.001--
Ovarian disorder21.11.02.004--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Stillbirth18.01.02.002; 08.04.01.006--Not Available
Supernumerary nipple21.05.04.020; 03.03.03.001--Not Available
Swelling08.01.03.015--Not Available
Trisomy 2103.20.01.002; 19.21.06.005; 17.03.07.005; 02.08.02.003--Not Available
Ventricular septal defect02.04.02.007; 03.07.02.001--Not Available
Contusion15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001--
The 1th Page    1 2    Next   Last    Total 2 Pages